A medical expert who says he was forced to resign after voicing concerns about Organon Pharmaceuticals’ attempts to conceal serious bleeding caused by the blood thinner Arixtra has sued the company.
Jeffery Feldstein, the company’s former associate director of medical services, says Organon hired him to analyze information about the drug, which was intended to reduce the risk of blood clots for orthopedic patients, Courthouse News Service reports.
But Feldstien says the company “blended” studies of knee replacement and hip replacement patients in order to obscure 11 cases of serious bleeding. When Feldstien expressed concerns, he says he was harassed, called insubordinate and given a disciplinary warning. He eventually resigned.
From Courthouse News Service:
Feldstein says that Organon “had budgeted approximately $23 million for the calendar year 2001 for symposia and other promotional purposes to serve Arixtra.”
Feldstein says that later e-mails he received from supervisors said that “we have the flexibility to influence selection of speakers, topics and content to ensure the symposium complements our abstract presentations and our product messages.”
Organon was approved by the FDA in 2001.


